Currently, Ultragenyx Pharmaceutical Inc [RARE] is trading at $32.02, up 1.81%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RARE shares have gain 6.06% over the last week, with a monthly amount glided 5.64%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On June 06, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $67 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $77 on April 22, 2024. Wells Fargo initiated its recommendation with a Overweight and recommended $72 as its price target on December 08, 2023. In a note dated June 06, 2023, Evercore ISI upgraded an Outperform rating on this stock and boosted its target price from $60 to $80.
This stock has fluctuated between a low of $25.81 and a high of $57.99 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $103.64 within the next 12 months. Ultragenyx Pharmaceutical Inc [NASDAQ: RARE] shares were valued at $32.02 at the most recent close of the market. An investor can expect a potential return of 223.67% based on the average RARE price forecast.
Analyzing the RARE fundamentals
Trailing Twelve Months sales for Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] were 610.16M which represents 13.24% growth. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -0.83%, Pretax Profit Margin comes in at -0.87%, and Net Profit Margin reading is -0.87%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -2.37 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of5.84.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ultragenyx Pharmaceutical Inc [NASDAQ:RARE] is 2.45. Also, the Quick Ratio is 2.30, while the Cash Ratio stands at 0.63. Considering the valuation of this stock, the price to sales ratio is 5.06, the price to book ratio is 20.36.
Transactions by insiders
Recent insider trading involved Huizenga Theodore Alan, SVP, Chief Accounting Officer, that happened on Sep 18 ’25 when 64.0 shares were sold. Officer, KARAH PARSCHAUER completed a deal on Sep 12 ’25 to buy 2450.0 shares. Meanwhile, EVP and Chief Legal Officer Parschauer Karah Herdman sold 2450.0 shares on Sep 12 ’25.
